Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer''s, Parkinson''s, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer''s and Parkinson''s diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer''s disease; and AL003, which is in Phase Ib clinical trial for the treatment of Alzheimer''s disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer''s disease; and 8 candidates in immuno-neurology/immuno-oncology field comprise ADP012, ADP016, ADP017, ADP023, ADP026, ADP122, ADP009, and ADP022. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Kontrakty CFD to złożone instrumenty, które wiążą się z dużym ryzykiem gwałtownej straty środków na skutek zastosowania dźwigni finansowej. 76% inwestorów detalicznych odnotowuje straty w handlu kontraktami CFD z tym dostawcą. Powinieneś rozważyć, czy rozumiesz, jak działają kontrakty CFD i czy możesz sobie pozwolić na podjęcie wysokiego ryzyka utraty pieniędzy. Prosimy o zapoznanie się z naszym Oświadczeniem o ryzyku
Oceny i recenzje
Oceny i recenzje
